Implementation of the Management of Anticoagulation in the Periprocedural Period App into an Electronic Health Record: A Cost-Effectiveness Analysis

The Management of Anticoagulation in the Periprocedural Period (MAPPP) app is a free tool providing up-to-date guidelines on the periprocedural management of patients on long-term anticoagulants. After validating its effectiveness in the post-procedural period, we aimed to study its overall cost-eff...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and applied thrombosis/hemostasis Vol. 29; p. 10760296231154553
Main Authors: Wang, Jason J., Koulas, Ioannis, Myrka, Anne, Spyropoulos, Alex C.
Format: Journal Article
Language:English
Published: Los Angeles, CA SAGE Publications 01.01.2023
SAGE PUBLICATIONS, INC
SAGE Publishing
Subjects:
Anticoagulants
Clinical decision making
Clinical outcomes
Cost analysis
Cost-Effectiveness Analysis
Electronic Health Records
Health economics
Health informatics
Health technology assessment
Hospitalization
Humans
Mobile Applications
Original Manuscript
Perioperative care
Quality of life
health informatics
cost-effectiveness analysis
electronic health record
MAPPP
anticoagulation
periprocedural management
ISSN:1076-0296, 1938-2723, 1938-2723
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Management of Anticoagulation in the Periprocedural Period (MAPPP) app is a free tool providing up-to-date guidelines on the periprocedural management of patients on long-term anticoagulants. After validating its effectiveness in the post-procedural period, we aimed to study its overall cost-effectiveness. SF-12 surveys were sent to eligible patients, converted into SF-6D forms, and subsequently into quality-adjusted life years (QALYs) to calculate the incremental cost-effectiveness ratio (ICER). The number of 30-day readmissions was used to calculate hospitalization costs, utilizing publicly available data. From 1/1/2018 to 1/31/2019, 642 patients were screened for enrollment, with an overall response rate of 94% (164/175) among the consented and 49% (164/336) among all eligible patients. The average QALY score was 0.7134 (95% CI [0.6836, 0.7431]) for the patients whose treatment plan followed the MAPPP app recommendations (acceptance group) and 0.7104 (95% CI [0.6760, 0.7448]) for those who did not (rejection group), without statistically significant differences. The difference in ICER scores was −$429 866.67, with the negative sign demonstrating that acceptance was the dominant strategy. By utilizing QALYs and ICER scores we have shown that the acceptance of MAPPP app recommendations is the dominant strategy for the periprocedural management of patients on long-term anticoagulation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Co-first author.
ISSN:1076-0296
1938-2723
1938-2723
DOI:10.1177/10760296231154553